Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VTP-43742 in healthy volunteers and psoriasis
NCT03724292Phase 1Completed
- Sponsor
- Allergan
- Start
- Aug 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vimirogant in psoriasis (6 arms), sponsored by Allergan. Primary endpoint: Treatment-Emergent Adverse Events. Started Aug 2015; status: completed.
02
Drugs
vimirogant
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03724292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03724292.